NCT06546800View on ClinicalTrials.gov

SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

Active, not recruitingOBSERVATIONAL

Enrollment

1,100

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

February 27, 2029

Study Completion Date

February 27, 2029

Conditions

Respiratory Syncytial Virus Infection

Interventions

BIOLOGICAL

RSVpreF vaccine

Injection in the muscle, 1 dose 0.5mL

Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY